Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice

Background: There are no clinical studies comparing the efficacy of bevacizumab vs.aflibercept in association with folfiri in RAS mutated (RAS-M) metastatic colorectal cancer patients (mCRC) pretreated with folfox and bevacizumab. Patients and Methods: Consecutive RAS-M unresectable mCRC patients pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottaiano, Alessandro, Capozzi, Monica, Tafuto, Salvatore, De Stefano, Alfonso, De Divitiis, Chiara, Romano, Carmela, Avallone, Antonio, Nasti, Guglielmo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700318/
https://www.ncbi.nlm.nih.gov/pubmed/31456948
http://dx.doi.org/10.3389/fonc.2019.00766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700318/
https://www.ncbi.nlm.nih.gov/pubmed/31456948
http://dx.doi.org/10.3389/fonc.2019.00766

Ejemplares similares